HomeSuppliersPeptide LibraryCompareBlog⚠️ BlacklistHow it worksLog in
HomePeptide librarySemaglutide

SemaglutideStrong clinical evidence

GLP-1 agonist

A GLP-1 receptor agonist (Ozempic/Wegovy) extensively researched for type 2 diabetes and obesity/weight management.

⚙️ How it works

Mimics the gut hormone GLP-1, binding GLP-1 receptors in pancreas, brain and GI tract. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic appetite centres to increase satiety and reduce food intake.

🎯 What it's studied to help

Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.

Phase 3 trials in 25,000+ people show ~15% mean body-weight loss vs ~2.4% placebo.
Slows gastric emptying and modulates gut-brain signalling (also the source of GI side effects).
Cardiovascular outcome trials show reduced major cardiac events.

✍️ Share your experience with Semaglutide

Verify to leave a review
Sign in once (Google or email) so reviews stay genuine — one review per person, editable anytime.
Sign in to review

⭐ Reviews (0)

No reviews yet. If you've used Semaglutide, be the first to share what it helped with and any side effects.

⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.